Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Werewolf Therapeutics also faced a compliance issue with Nasdaq due to the passing of board member Dr. Alon Lazarus, reducing the audit committee members below the required number. Additionally, ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results